Targeting OPN itself may be less than optimal, since although blocking OPN action may slow FR/S MN degeneration, and so delay manifestation of clinical ALS symptoms, it may also inhibit OPN’s protective action via glial cells. This evidence concerns the gene SPP1 and amyotrophic lateral sclerosis.